Grey Wolf has assembled a broad and impressive team of professionals charged with realizing the therapeutic potential of ERAP inhibition. In particular, the company’s leadership includes highly-regarded industry executives with deep experience in operations, as well as successful track records in the discovery, development and commercialization of novel therapeutics.


The board of directors is comprised of seasoned industry executives with expertise that spans drug discovery and development, finance, operations, company creation, and M&A, among other relevant areas. The significant scientific expertise in the area of cancer shared by several board members is particularly valuable as the company advances its lead ERAP1 inhibitor as a next-generation immuno-oncology therapy.